You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


First patients enrolled for Priothera’s mocravimod trial

Priothera – a company focused on the development of a sphingosine 1 phosphate (S1P) receptor modulator compound – announced that the first patients have been enrolled in its MO-TRANS phase 2b/3 study evaluating mocravimod.